On the public citation graph

Trans-Pacific Partnership Provisions in Intellectual Property, Transparency, and Investment Chapters Threaten Access to Medicines in the US and Elsewhere

https://doi.org/10.1371/journal.pmed.1001970
0 signed · 46 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1017/s1474745617000386openalex-snapshot
Eli Lilly and Company v. The Government of Canada, Case No. UNCT/14/2
inferredcites →https://doi.org/10.1057/biosoc.2010.40openalex-snapshot
Demythologizing the high costs of pharmaceutical research
inferredcites →https://doi.org/10.1057/jgm.2008.6openalex-snapshot
The Value of Patent Term Extensions to the Pharmaceutical Industry in the USA
inferredcites →https://doi.org/10.1177/009885880803400209openalex-snapshot
Ending Drug Registration Apartheid: Taming Data Exclusivity and Patent/Registration Linkage
inferredcites →https://doi.org/10.1371/journal.pmed.1001460openalex-snapshot
Patented Drug Extension Strategies on Healthcare Spending: A Cost-Evaluation Analysis
inferredcites →https://doi.org/10.1377/hlthaff.2012.0107openalex-snapshot
Secondary Patenting Of Branded Pharmaceuticals: A Case Study Of How Patents On Two HIV Drugs Could Be Extended For Decades
inferredcites →https://doi.org/10.2139/ssrn.1993034openalex-snapshot
Settlement of India/EU WTO Dispute re Seizures of In-Transit Medicines: Why the Proposed EU Border Regulation Isn't Good Enough
inferredcites →https://doi.org/10.2139/ssrn.2667062openalex-snapshot
Corporate Power Unbound: Investor-State Arbitration of IP Monopolies on Medicines - Eli Lilly v. Canada and the Trans-Pacific Partnership Agreement
inferredcites →https://doi.org/10.2471/blt.12.113886openalex-snapshot
Balancing options for health research and development

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3134106openalex-extracted
Innovation Nationalism
inferred← citeshttps://doi.org/10.2139/ssrn.3392464openalex-extracted
inferred← citeshttps://doi.org/10.1001/journalofethics.2016.18.7.pfor1-1607openalex-snapshot
Protecting Pharmaceutical Patents and Test Data: How the Trans-Pacific Partnership Agreement Could Affect Access to Medicines in the US and Abroad
inferred← citeshttps://doi.org/10.1007/978-3-030-83114-1_11openalex-snapshot
The Impact of ‘TRIPS-Plus’ Rules on the Use of TRIPS Flexibilities: Dealing with the Implementation Challenges
inferred← citeshttps://doi.org/10.1007/s11151-020-09760-4openalex-snapshot
A “Primarily Property” Presumption Is—Still—Really Needed for the IP/Antitrust Interface
inferred← citeshttps://doi.org/10.1007/s11904-018-0390-3openalex-snapshot
The Syndemic of Opioid Misuse, Overdose, HCV, and HIV: Structural-Level Causes and Interventions
inferred← citeshttps://doi.org/10.1007/s40319-018-0758-3openalex-snapshot
Assessing Access to Medicines in Preferential Trade Agreements: From the Trans-Pacific Partnership to the Comprehensive and Progressive Agreement for Trans-Pacific Partnership
inferred← citeshttps://doi.org/10.1017/lst.2022.43openalex-snapshot
Pharmaceutical patent law and policy in Africa: a survey of selected SADC member states
inferred← citeshttps://doi.org/10.1017/s1744133125100261openalex-snapshot
An opportunity to remove harmful intellectual property provisions from the Comprehensive and Progressive Agreement for Trans-Pacific Partnership
inferred← citeshttps://doi.org/10.1080/08853908.2017.1386143openalex-snapshot
Patents and the Trans-Pacific Partnership: How TPP-style intellectual property standards may exacerbate the access to medicines problem in the East African Community
inferred← citeshttps://doi.org/10.1080/09692290.2019.1624295openalex-snapshot
Patents, trade and medicines: past, present and future
inferred← citeshttps://doi.org/10.1080/17441692.2016.1256418openalex-snapshot
The Trans Pacific Partnership Agreement and access to HIV treatment in Vietnam
inferred← citeshttps://doi.org/10.1080/17441692.2017.1334807openalex-snapshot
The trends and constructive ambiguity in international agreements on intellectual property and pharmaceutical affairs: Implications for domestic legislations in low- and middle-income countries
inferred← citeshttps://doi.org/10.1111/jwip.12091openalex-snapshot
Broadening the conversation on the TRIPS agreement: Access to medicines includes addressing access to medical devices
inferred← citeshttps://doi.org/10.1136/jech-2020-215104openalex-snapshot
Glossary on free trade agreements and health part 1: the shift from multilateralism and the rise of ‘WTO-Plus’ provisions
inferred← citeshttps://doi.org/10.1142/s0116110522500093openalex-snapshot
The Social Costs of Success: The Impact of World Trade Organization Rules on Insulin Prices in Bangladesh upon Graduation from Least Developed Country Status
inferred← citeshttps://doi.org/10.1177/09749284231225835openalex-snapshot
India’s Distinct but Opposing Patent Model Is Under Pressure: Prospects and Challenges in the Global Arena
inferred← citeshttps://doi.org/10.1177/1010539516676338openalex-snapshot
The Regional Comprehensive Economic Partnership, Intellectual Property Protection, and Access to Medicines
inferred← citeshttps://doi.org/10.1177/1024529417729325openalex-snapshot
Trade governance at a crossroads: Continuity and change in uncertain times
inferred← citeshttps://doi.org/10.1177/1468018117734153openalex-snapshot
The Trans Pacific Partnership Agreement, intellectual property and medicines: Differential outcomes for developed and developing countries
inferred← citeshttps://doi.org/10.1177/1741134319839447openalex-snapshot
The Trans-Pacific Partnership’s patent linkage: Unfriending or befriending the right to biologics?
inferred← citeshttps://doi.org/10.1186/s12992-018-0423-0openalex-snapshot
Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States
inferred← citeshttps://doi.org/10.1186/s12992-019-0528-0openalex-snapshot
Impacts of intellectual property provisions in trade treaties on access to medicine in low and middle income countries: a systematic review
inferred← citeshttps://doi.org/10.1186/s12992-020-00633-9openalex-snapshot
Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis
inferred← citeshttps://doi.org/10.1186/s12992-021-00739-8openalex-snapshot
When actions do not match aspirations - comparison of the European Union policy claims against what has been negotiated for health services, trade and investment
inferred← citeshttps://doi.org/10.1186/s12992-022-00829-1openalex-snapshot
Perceived impact of the patent linkage system on pharmaceutical market from the viewpoint of the domestic manufacturers in South Korea
inferred← citeshttps://doi.org/10.1186/s12992-024-01053-9openalex-snapshot
The potential impact of the Comprehensive and Progressive Agreement for Trans-Pacific Partnership on Thailand’s hepatitis C treatment program
inferred← citeshttps://doi.org/10.1515/bjals-2016-0012openalex-snapshot
The Trans-Pacific Partnership
inferred← citeshttps://doi.org/10.15171/ijhpm.2016.129openalex-snapshot
Advancing Public Health on the Changing Global Trade and Investment Agenda Comment on "The Trans-Pacific Partnership: Is It Everything We Feared for Health?"
inferred← citeshttps://doi.org/10.18294/sc.2016.1088openalex-snapshot
Apuntes para una estrategia de medicamentos “esenciales” para Latinoamérica
inferred← citeshttps://doi.org/10.23889/suthesis.55173openalex-snapshot
Bridging the gap between the distinct regulatory frameworks of international trade law and UN human rights law: Access to medicines
inferred← citeshttps://doi.org/10.29057/xikua.v11i21.9923openalex-snapshot
La importancia de la biotecnología en las ciencias de la salud: una revisión
inferred← citeshttps://doi.org/10.29057/xikua.v11i22.10566openalex-snapshot
Influencia del deterioro del medio ambiente sobre la salud renal: una revisión narrativa.
inferred← citeshttps://doi.org/10.4337/9781785364723.00036openalex-snapshot
Bibliography
inferred← citeshttps://doi.org/10.5530/srp.2019.2.07openalex-snapshot
Impact of People Access to Public Drugs on Substance Abuse and Delinquency Behavior in Thailand: Mediating Role of Life Satisfaction
inferred← citeshttps://doi.org/10.6084/m9.figshare.19395919openalex-snapshot
Additional file 1 of Perceived impact of the patent linkage system on pharmaceutical market from the viewpoint of the domestic manufacturers in South Korea
inferred← citeshttps://doi.org/10.6084/m9.figshare.26733247openalex-snapshot
Additional file 1 of The potential impact of the Comprehensive and Progressive Agreement for Trans-Pacific Partnership on Thailand’s hepatitis C treatment program
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.